- Home
- DFDV vs ACRS Comparison
DFDV vs ACRS Comparison
Compare DFDV & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFDV
- ACRS
- Stock Information
- Founded
- DFDV 2018
- ACRS 2012
- Country
- DFDV United States
- ACRS United States
- Employees
- DFDV N/A
- ACRS N/A
- Industry
- DFDV Finance: Consumer Services
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- DFDV Finance
- ACRS Health Care
- Exchange
- DFDV Nasdaq
- ACRS Nasdaq
- Market Cap
- DFDV 219.8M
- ACRS 230.8M
- IPO Year
- DFDV N/A
- ACRS 2015
- Fundamental
- Price
- DFDV $7.55
- ACRS $2.85
- Analyst Decision
- DFDV Buy
- ACRS Strong Buy
- Analyst Count
- DFDV 1
- ACRS 5
- Target Price
- DFDV $45.00
- ACRS $9.75
- AVG Volume (30 Days)
- DFDV 1.7M
- ACRS 1.4M
- Earning Date
- DFDV 11-12-2025
- ACRS 11-06-2025
- Dividend Yield
- DFDV N/A
- ACRS N/A
- EPS Growth
- DFDV N/A
- ACRS N/A
- EPS
- DFDV 4.13
- ACRS N/A
- Revenue
- DFDV $7,526,660.00
- ACRS $15,742,000.00
- Revenue This Year
- DFDV $312.92
- ACRS N/A
- Revenue Next Year
- DFDV $141.18
- ACRS N/A
- P/E Ratio
- DFDV $1.81
- ACRS N/A
- Revenue Growth
- DFDV 313.28
- ACRS N/A
- 52 Week Low
- DFDV $0.53
- ACRS $1.05
- 52 Week High
- DFDV $53.88
- ACRS $4.24
- Technical
- Relative Strength Index (RSI)
- DFDV 35.78
- ACRS 67.71
- Support Level
- DFDV $6.02
- ACRS $2.34
- Resistance Level
- DFDV $7.75
- ACRS $2.57
- Average True Range (ATR)
- DFDV 0.74
- ACRS 0.22
- MACD
- DFDV 0.18
- ACRS 0.03
- Stochastic Oscillator
- DFDV 51.42
- ACRS 96.18
About DFDV DeFi Development Corp. Common Stock
DeFi Development Corp is an AI-powered online platform that connects the commercial real estate industry by providing data and software subscriptions as well as value-add services to multifamily and commercial property professionals.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.